Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study of Bivalent RSV Prefusion F Protein Vaccines (SCB-1019/SCB-1019T) in Healthy Adults

NCT06194318 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.

NCT NCT06194318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06194318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study of Bivalent RSV Prefusion F Protein Vaccines (SCB-1019/SCB-1019T) in Healthy Adults
Lead sponsor
Clover Biopharmaceuticals AUS Pty
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2023
Completion date
May 7, 2025
Enrollment
160 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus vaccination